CA
NZ
UK
AU
IND
US
…
Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. Argenica Therapeutics Limited was incorporated in 2019 and is based in Nedlands, Australia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Argenica Therapeutics Ltd is an Australia-listed life-sciences company focused on therapeutic research and development, though public disclosure on its specific programs and development stage is limited. Long-term growth drivers may include pipeline advancement, successful regulatory outcomes, and commercialization or licensing arrangements, which could support value creation for investors seeking biotech exposure.
Principal risks include clinical or regulatory failure, limited operating history and public information, funding requirements and dilution, and competitive pressures in its therapeutic area.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -5.34M | -7.17M | -7.57M | -4.82M | -4.09M |
| Net income | -1.37M | -7.17M | -5.48M | -4.82M | -4.09M |
| Selling general administrative | - | 0.98M | 0.85M | 2.25M | 1.75M |
| Selling and marketing expenses | - | 1.79M | 1.40M | - | - |
| Gross profit | - | 3.21M | 2.60M | - | - |
| Ebit | - | - | -7.57M | -4.87M | -4.09M |
| Ebitda | -7.06M | - | -1.90M | -4.81M | -4.09M |
| Depreciation and amortization | - | 7.68M | 5.67M | - | - |
| Operating income | -7.06M | -7.68M | -5.67M | -6.56M | -4.09M |
| Other operating expenses | 7.06M | 10.90M | 8.27M | - | 4.35M |
| Interest expense | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Tax provision | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | - | 0.51M | 0.19M | 0.00M | 0.00M |
| Net interest income | - | 0.51M | 0.19M | 0.06M | 0.00M |
| Income tax expense | -3.97M | - | -2.09M | - | - |
| Total revenue | - | 3.21M | 2.60M | 0.06M | 0.00M |
| Total operating expenses | 7.06M | 10.90M | 8.27M | - | 4.35M |
| Total other income expense net | 1.72M | 0.51M | -1.90M | 1.75M | 0.26M |
| Net income from continuing ops | - | -7.17M | -5.48M | -4.82M | -4.09M |
| Net income applicable to common shares | - | -7.17M | -5.48M | -4.82M | -4.09M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 6.52M | 11.04M | 16.38M | 9.54M | 9.04M |
| Intangible assets | 0.00M | 0.00M | - | 0.00M | 0.00M |
| Other current assets | 0.06M | - | 0.09M | 0.05M | - |
| Total liab | 0.61M | 3.80M | 2.43M | 1.87M | 0.74M |
| Total stockholder equity | 5.90M | 7.24M | 13.95M | 7.67M | 8.31M |
| Other current liab | 0.19M | - | 1.02M | 0.68M | 0.06M |
| Common stock | 29.82M | - | 28.43M | 16.62M | 13.07M |
| Capital stock | - | 29.63M | - | 16.62M | 13.07M |
| Retained earnings | -24.10M | -22.73M | -15.69M | -10.32M | -5.50M |
| Other assets | - | - | 0.00M | - | - |
| Cash | 6.36M | 10.56M | 15.91M | 9.29M | 8.91M |
| Total current liabilities | 0.61M | 3.80M | 2.43M | 1.87M | 0.74M |
| Net debt | -6.36M | - | -15.91M | - | -8.91M |
| Short term debt | - | - | - | 0.00M | 0.00M |
| Other stockholder equity | - | - | - | 1.37M | 0.75M |
| Total current assets | 6.52M | 11.04M | 16.38M | 9.54M | 9.04M |
| Net tangible assets | - | - | - | 7.67M | 8.31M |
| Short term investments | - | - | - | 0.05M | - |
| Net receivables | 0.10M | - | 0.37M | 0.15M | 0.07M |
| Accounts payable | 0.43M | 2.88M | 1.40M | 1.14M | 0.67M |
| Accumulated other comprehensive income | 0.18M | - | 1.21M | - | 0.75M |
| Non current assets total | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Long term debt total | - | - | - | 0.00M | 0.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | 0.00M | 0.05M | -0.05M | -0.05M |
| Change to liabilities | - | - | - | 1.12M | 0.29M |
| Total cashflows from investing activities | - | - | 0.05M | -0.05M | -0.05M |
| Total cash from financing activities | -0.00M | 0.35M | 11.63M | 3.73M | 5.13M |
| Change to operating activities | - | - | - | 0.01M | 0.02M |
| Net income | -1.37M | -7.17M | -5.48M | -4.82M | -4.09M |
| Change in cash | -4.19M | -5.36M | 6.62M | 0.37M | 1.77M |
| Begin period cash flow | 10.56M | 15.91M | 9.29M | 8.91M | 7.14M |
| End period cash flow | 6.36M | 10.56M | 15.91M | 9.29M | 8.91M |
| Total cash from operating activities | -4.19M | -5.70M | -5.06M | -3.30M | -3.36M |
| Issuance of capital stock | - | 0.35M | 11.63M | 3.73M | 5.13M |
| Other cashflows from investing activities | - | - | 0.05M | -0.05M | - |
| Change to account receivables | 0.35M | -0.03M | -0.23M | -0.07M | -0.00M |
| Sale purchase of stock | - | - | 11.63M | 3.73M | 5.13M |
| Other cashflows from financing activities | - | - | 0.05M | 0.00M | 0.00M |
| Change to netincome | - | - | - | 0.46M | 0.43M |
| Capital expenditures | 4.19M | 0.00M | 5.06M | 0.00M | 0.00M |
| Change in working capital | -2.86M | -0.03M | 0.28M | 0.78M | 0.00M |
| Stock based compensation | - | 0.11M | 0.14M | - | - |
| Other non cash items | 0.03M | 1.38M | -0.07M | - | - |
| Free cash flow | - | -5.70M | -5.06M | -3.30M | -3.36M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(AUD) |
Price
(AUD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| AGN Argenica Therapeutics Ltd |
-0.01 5.00% |
0.10 | - | - | 2.23 | 2.18 | -7.28 |
| CSL CSL Ltd |
-0.36 0.18% |
202.04 | - | 22.57 | 6.15 | 4.48 | 10.06 |
| TLX TELIX Pharmaceuticals Ltd |
-0.41 2.91% |
13.67 | 93.87 | 166.67 | 5.37 | 6.37 | 47.29 |
| NEU Neuren Pharmaceuticals Ltd |
- -% |
23.24 | 154.93 | 36.36 | 42.38 | 7.52 | 160.40 |
| MSB Mesoblast Ltd |
-0.14 6.45% |
2.03 | - | 454.55 | 23.43 | 3.36 | -9.86 |
Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. Argenica Therapeutics Limited was incorporated in 2019 and is based in Nedlands, Australia.
| Name | Title | Year Born |
|---|---|---|
| Dr. Liz Dallimore B.Sc., M.B.A., Ph.D. | CEO, MD & Director | NA |
| Dr. Samantha South GAICD, MBA, Ph.D. | COO & Exec. Director | NA |
| Ms. Emma Waldon | CFO & Company Sec. | 1976 |
| Prof. Bruno Philip Meloni | Chief Scientific Officer | NA |
| Dr. Meghan Thomas | Head of Clinical Devel. | NA |
| Ms. Emma Waldon | CFO & Company Secretary | 1976 |
| Ms. Emma Waldon | CFO & Company Secretary | 1976 |
| Ms. Emma Waldon | CFO & Company Secretary | 1976 |
| Ms. Emma Waldon | CFO & Company Secretary | 1976 |
| Ms. Emma Waldon | CFO & Company Secretary | 1976 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.61%
Communication Services
-0.21%
Consumer Cyclical
-0.26%
Consumer Defensive
-0.37%
Energy
+0.23%
Financial Services
-0.43%
Financials
+0.39%
Healthcare
+0.88%
Industrials
+0.36%
Real Estate
-0.51%
Technology
+1.35%
Utilities
+0.19%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...